A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer

NCT ID: NCT01545882

Last Updated: 2020-05-07

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-05-31
• Study Completion Date: 2013-07-31

Brief Summary

This study is being offered to patients who have hormone resistant prostate cancer (HRPC). This means that their prostate cancer is no longer responding to standard hormonal therapy.

The purpose of this study is to determine whether Degarelix will be able to stop the PSA from rising in patients with hormone resistant prostate cancer.

Detailed Description

This is a phase II study of a GnRH antagonist drug, Degarelix, for use in hormone resistant prostate cancer patients who have had biochemical PSA progression despite the use of total androgen blockade therapy. Patients will receive at least six monthly injections of Degarelix unless the patient shows radiographic or symptomatic disease progression, intolerable toxicity or decides to withdraw from the study. Patients will be evaluated for measures of efficacy, toxicity and disease progression during treatment and afterwards until radiologically confirmed metastatic disease progression or until the patient is removed from the study.

Overall objective:

The efficacy of Degarelix as a treatment for HRPC will be evaluated

Conditions

Prostatic Neoplasms

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Degarelix

Degarelix treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.

Group Type: EXPERIMENTAL

Degarelix

Intervention Type: DRUG

Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.

Interventions

Degarelix

Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.

Intervention Type: DRUG

Other Intervention Names

Firmagon

Eligibility Criteria

Inclusion Criteria

• Prior trial of total androgen blockade
• Confirmed biochemical PSA progression on agonist therapy, defined as ≥ 50% increase in PSA between 2 measurements, taken at least 1 week apart. In patients that are currently on total androgen blockade (LHRH agonist plus non-steroidal anti-androgen) there must be a trial withdrawal of androgen receptor antagonists to ensure that there is no PSA response (6 weeks for bicalutamide and 4 weeks for flutamide or nilutamide).
• Radiologically confirmed non-metastatic disease within 90 days of registration based on negative chest radiographs, CT Scan Abdomen/Pelvis and Bone scan
• ECOG ≤ 2
• Age ≥ 18 years
• Serum testosterone of ≤ 50 mg/dl
• PSA ≥ 2.0 ng/ml
• White blood cell count ≥ 3000/mm3
• Platelets ≥ 100,000/mm3
• Serum creatinine ≤ 1.5 x upper limits of normal
• Bilirubin ≤ 1.5 x upper limits of normal
• Alanine transaminase ≤ 1.25 x upper limits of normal
• Estimated life expectancy of at least 12 months
• Able and willing to sign informed consent

Exclusion Criteria

• Prior treatment with chemotherapy, radiopharmaceuticals, estrogen, PC-SPES, ketoconazole or other second line hormonal therapy (other than non-steroidal anti-androgens or Androcur)
• Known allergy to GnRH agonists or antagonists
• Previous treatment with Degarelix
• Major surgery within 4 weeks of registration
• Grade ≥ 3 peripheral neuropathy
• Severe, active co-morbidity such as unstable angina, congestive heart failure or myocardial infarction within the last 6 months or congenital long QT syndrome
• Acute deep vein thrombosis or pulmonary embolism
• Taking anti-arrhythmia medication
• Second malignancy other than non-melanoma skin cancer unless disease free ≥ 5 years.
• Prior orchiectomy for prostate cancer
• PSA > 100 ng/mL

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Ottawa Hospital Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Shawn Malone, Dr.

Role: PRINCIPAL_INVESTIGATOR

The Ottawa Hospital Cancer Centre

Locations

London Regional Cancer Centre

London, Ontario, Canada

Ottawa Hospital Cancer Centre

Ottawa, Ontario, Canada

Princess Margeret Hospital

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

OTT10-06

Identifier Type: OTHER

Identifier Source: secondary_id

10-059

Identifier Type: -

Identifier Source: org_study_id